

# **Nucleic Acid Therapeutics CDMO Market - A Global and Regional Analysis: Focus on Product, Technology, and End User - Analysis and Forecast, 2021-2030**

<https://marketpublishers.com/r/N37950CBE7A3EN.html>

Date: September 2021

Pages: 180

Price: US\$ 7,000.00 (Single User License)

ID: N37950CBE7A3EN

## **Abstracts**

Market Report Coverage - Nucleic Acid Therapeutics CDMO

Market Segmentation

Product – Standard Nucleic Acid, Micro-Scale Nucleic Acid, Large-Scale Nucleic Acid, Custom Nucleic Acid, Modified Nucleic Acid, Primers, Probes, Other Nucleic Acid, Other Services

Chemical Synthesis – Solid-Phase Oligonucleotide Synthesis, Liquid-Phase Oligonucleotide Synthesis

Technology – Column-Based Method, Microarray-Based Method

End User – Pharmaceutical Companies, Academic Research Institute, Diagnostic Laboratories

Regional Segmentation

America – U.S., Canada

Europe – Germany, U.K., France, Italy, Spain, Rest-of-Europe

Asia-Pacific – Japan, China, India, Australia, Rest-of-Asia-Pacific

Rest-of-the-World

Drivers

Pharmaceutical Market Toward Innovative Biologic and Cell and Gene Therapy Products

Manufacturing Cost at CDMOs

Nucleic Acid Therapeutics

Manufacturing

to Wide Variety of Nucleic Acids

Companies

Technology

g AG, Biospring GmbH, Corden Pharma International, Danaher Corporation, Guangzhou Ruibo  
ited, Merck KGaA, Nippon Shokubai Co., Ltd., Nitto Denko Avecia Inc., QIAGEN N.V., ST Pharm Co  
ted, Thermo Fisher Scientific Inc., Wuxi AppTec, Yamasa Corporation

global nucleic acid therapeutics CDMO market?

players to stand out in this global nucleic acid therapeutics CDMO market?

global nucleic acid therapeutics CDMO market?

nucleic acid therapeutics CDMO market?

and a push to product development within the global nucleic acid therapeutics CDMO market?

nucleic acid therapeutics CDMO market?

therapeutics CDMO market is anticipated to witness a massive rise in demand during the forecast

market expected to grow during the forecast period, and what revenue is expected to be generated by

molecular pathways that are critical in the disease molecule interaction have offered an unprecedented growth. However, to keep with the manufacturing and development of such therapies, the pharmaceutical companies are looking for contract manufacturing company (CMO) which are the viable alternatives to the in-house development of drugs. These CMOs to become an integral part of such pharmaceutical companies' value chain.

and the rising need for pharmaceuticals have resulted in the expansion of the global market for nucleic

sequence information that has the potential to revolutionize the way diseases are categorized and treated. It is likely to be superseded by the molecular characterization of the disease. The fact that certain genes are being targeted for specific therapeutics. Antisense oligonucleotides represent a technology that can play multiple roles in this field. The FDA and EMA and many more in the pipeline implying the reliance and acceptance over the

type, application, technology, end users, and region. Each of these segments covers the snapshot of the market, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Market on the global level has created a buzz among companies to invest in the manufacturing of nucleic acid therapeutics CDMO market witnessed approximately 31 notable key developments. Mergers and acquisitions, 24 synergistic developments (partnerships, collaborations, agreements,

nucleic acid therapeutics CDMO manufacturing due to improved healthcare infrastructure, rise in per From this, Latin America and the Asia-Pacific region are anticipated to grow at the fastest CAGR during

## Contents

### 1 MARKETS

- 1.1 Industry Outlook
  - 1.1.1 Global Nucleic Acid Therapeutics CDMO Market Overview
- 1.2 Product Definition
- 1.3 Global Nucleic Acid Therapeutics CDMO Market Footprint, (\$ Million), 2020-2030
- 1.4 Current Nucleic Acid Therapeutic CDMOs Landscape
- 1.5 Significant Usage of Nucleic Acid in Therapeutics
- 1.6 Types of Nucleic Acid Synthesized for Therapeutics
  - 1.6.1 Anti-Sense Oligonucleotides (ASOs) and DNA Aptamers
  - 1.6.2 RNA interference [RNAi] and short interfering RNAs [siRNAs]
  - 1.6.3 MicroRNAs
  - 1.6.4 RNA Aptamers and RNA Decoys
  - 1.6.5 Ribozymes
  - 1.6.6 Circular RNAs
- 1.7 Market Dynamics
  - 1.7.1 Market Drivers
    - 1.7.1.1 Accelerating Shift of the Pharmaceutical Market Toward Innovative Biologic and Cell and Gene Therapy Products
    - 1.7.1.2 Reduction in Overall Manufacturing Cost at CDMOs
    - 1.7.1.3 Rising Approvals of Nucleic Acid Therapeutics
  - 1.7.2 Restraints
    - 1.7.2.1 Lack of Expertise in Nucleic Acid Manufacturing
    - 1.7.2.2 Supply Chain and Logistical Challenges
    - 1.7.2.3 Difficult Therapeutic Classification Due to Wide Variety of Nucleic Acids
  - 1.7.3 Opportunities
    - 1.7.3.1 Increasing Outsourcing Trend Among Pharmaceutical Companies
    - 1.7.3.2 Accelerating Research and Development Along with Technology
    - 1.7.3.3 Growth in Developing Countries

### 2 COMPETITIVE LANDSCAPE

- 2.1 New Offerings and Funding and Investments
- 2.2 Regulatory and Legal
- 2.3 Mergers and Acquisitions
- 2.4 Synergistic Activities
- 2.5 Market Share Analysis

## 2.6 Growth Share Analysis

## 3 CHEMICAL SYNTHESIS METHOD

### 3.1 Overview

#### 3.1.1 Solid-Phase Oligonucleotide Synthesis

##### 3.1.1.1 Advantages and Challenges of SPOS

##### 3.1.1.2 Method

###### 3.1.1.2.1 Deprotecting/Detritylation

###### 3.1.1.2.2 Coupling

###### 3.1.1.2.3 Oxidation/Sulfurization

###### 3.1.1.2.4 Capping

##### 3.1.1.3 Cleavage and Deprotection

##### 3.1.1.4 Purification

#### 3.1.2 Liquid-Phase Oligonucleotide Synthesis

##### 3.1.2.1 Advantages and Challenges of LPOS

## 4 TECHNOLOGY

### 4.1 Overview

#### 4.1.1 Column-Based Method

#### 4.1.2 Microarray-Based Method

## 5 END-USER

### 5.1 Overview

#### 5.1.1 Pharmaceutical Companies

#### 5.1.2 Academic Research Institute

#### 5.1.3 Diagnostic Laboratories

## 6 PRODUCTS

### 6.1 Global Nucleic Acid Therapeutics CDMO Market (by Product)

#### 6.1.1 Standard Nucleic Acid

#### 6.1.2 Micro-Scale Nucleic Acid

#### 6.1.3 Large-Scale Nucleic Acid

#### 6.1.4 Custom Nucleic Acid

#### 6.1.5 Modified Nucleic Acid

#### 6.1.6 Primers

- 6.1.7 Probes
- 6.1.8 Other Nucleic Acid
- 6.1.9 Other Services

## **7 REGIONS**

- 7.1 Overview
- 7.2 North America
  - 7.2.1 U.S.
  - 7.2.2 Canada
- 7.3 Europe
  - 7.3.1 Germany
  - 7.3.2 U.K.
  - 7.3.3 France
  - 7.3.4 Italy
  - 7.3.5 Spain
  - 7.3.6 Rest-of-Europe
- 7.4 Asia-Pacific
  - 7.4.1 China
  - 7.4.2 India
  - 7.4.3 Japan
  - 7.4.4 Australia
  - 7.4.5 Rest-of-Asia-Pacific
- 7.5 Rest-of-the-World

## **8 MARKETS - COMPETITIVE BENCHMARKING & COMPANY PROFILES**

- 8.1 Competitive Benchmarking
- 8.2 Agilent Technologies, Inc.
  - 8.2.1 Company Overview
  - 8.2.2 Role of Agilent Technologies, Inc. in the Global Nucleic Acid Therapeutics CDMO Market
  - 8.2.3 Financials
  - 8.2.4 Key Insights About Financial Health of the Company
  - 8.2.5 SWOT Analysis
- 8.3 Ajinomoto Co. Inc.
  - 8.3.1 Company Overview
  - 8.3.2 Role of Ajinomoto Co. Inc. in Global Nucleic Acid Therapeutics CDMO Market
  - 8.3.3 Financials

- 8.3.4 SWOT Analysis
- 8.4 Bachem Holding AG.
  - 8.4.1 Company Overview
  - 8.4.2 Role of Bachem Holding AG. in Global Nucleic Acid Therapeutics CDMO Market
  - 8.4.3 SWOT Analysis
- 8.5 Biospring GmbH
  - 8.5.1 Company Overview
  - 8.5.2 Role of Biospring GmbH in Global Nucleic Acid Therapeutics CDMO Market
  - 8.5.3 SWOT Analysis
- 8.6 Corden Pharma International
  - 8.6.1 Company Overview
  - 8.6.2 Role of Corden Pharma International in the Global Nucleic Acid Therapeutics CDMO Market
  - 8.6.3 SWOT Analysis
- 8.7 Danaher Corporation
  - 8.7.1 Company Overview
  - 8.7.2 Role of Danaher Corporation in the Global Nucleic Acid Therapeutics CDMO Market
  - 8.7.3 Financials
  - 8.7.4 Key Insights About Financial Health of the Company
  - 8.7.5 SWOT Analysis
- 8.8 Guangzhou Ruibo Biotechnology Co., Ltd.
  - 8.8.1 Company Overview
  - 8.8.2 Role of Guangzhou Ruibo Biotechnology Co., Ltd. in the Global Nucleic Acid Therapeutics CDMO Market
  - 8.8.3 SWOT Analysis
- 8.9 KNC Laboratories Co., Ltd.
  - 8.9.1 Company Overview
  - 8.9.2 Role of KNC Laboratories Co., Ltd. in the Global Nucleic Acid Therapeutics CDMO Market
  - 8.9.3 Financials
  - 8.9.4 SWOT Analysis
- 8.1 LGC Limited
  - 8.10.1 Company Overview
  - 8.10.2 Role of LGC Limited in the Global Nucleic Acid Therapeutics CDMO Market
  - 8.10.3 Financials
  - 8.10.4 Key Insights About Financial Health of the Company
  - 8.10.5 SWOT Analysis
- 8.11 Merck KGaA



- 8.11.1 Company Overview
- 8.11.2 Role of Merck KGaA in the Global Nucleic Acid Therapeutics CDMO Market
- 8.11.3 Financials
- 8.11.4 Key Insights About Financial Health of the Company
- 8.11.5 SWOT Analysis
- 8.12 Nippon Shokubai Co., Ltd.
  - 8.12.1 Company Overview
  - 8.12.2 Role of Nippon Shokubai Co., Ltd. in the Global Nucleic Acid Therapeutics CDMO Market
  - 8.12.3 Financials
  - 8.12.4 Key Insights About Financial Health of the Company
  - 8.12.5 SWOT Analysis
- 8.13 Nitto Denko Avecia Inc.
  - 8.13.1 Company Overview
  - 8.13.2 Role of Nitto Denko Avecia Inc. in the Global Nucleic Acid Therapeutics CDMO Market
  - 8.13.3 SWOT Analysis
- 8.14 QIAGEN N.V.
  - 8.14.1 Company Overview
  - 8.14.2 Role of QIAGEN N.V. in the Global Nucleic Acid Therapeutics CDMO Market
  - 8.14.3 Financials
  - 8.14.4 Key Insights About Financial Health of the Company
  - 8.14.5 SWOT Analysis
- 8.15 ST Pharm Co Ltd
  - 8.15.1 Company Overview
  - 8.15.2 Role of ST Pharm Co Ltd in Global Nucleic Acid Therapeutics CDMO Market
- 8.16 Sumitomo Chemical Co., Ltd.
  - 8.16.1 Company Overview
  - 8.16.2 Role of Sumitomo Chemical Co., Ltd. in the Global Nucleic Acid Therapeutics CDMO Market
  - 8.16.3 Financials
  - 8.16.4 Key Insights About Financial Health of the Company
  - 8.16.5 SWOT Analysis
- 8.17 Syngene International Limited
  - 8.17.1 Company Overview
  - 8.17.2 Role of Syngene International Limited in the Global Nucleic Acid Therapeutics CDMO Market
  - 8.17.3 Financials
  - 8.17.4 Key Insights About Financial Health of the Company

#### 8.17.5 SWOT Analysis

### 8.18 Thermo Fisher Scientific Inc.

#### 8.18.1 Company Overview

#### 8.18.2 Role of Thermo Fisher Scientific Inc. in the Global Nucleic Acid Therapeutics

### CDMO Market

#### 8.18.3 Financials

#### 8.18.4 Key Insights About Financial Health of the Company

#### 8.18.5 SWOT Analysis

### 8.19 Wuxi AppTec

#### 8.19.1 Company Overview

#### 8.19.2 Role of Wuxi AppTec in the Global Nucleic Acid Therapeutics CDMO Market

#### 8.19.3 Financials

#### 8.19.4 Key Insights About Financial Health of the Company

#### 8.19.5 SWOT Analysis

### 8.2 Yamasa Corporation

#### 8.20.1 Company Overview

### 8.20.2 Role of Yamasa Corporation in the Global Nucleic Acid Therapeutics CDMO Market

#### 8.20.3 SWOT Analysis

## List Of Figures

### LIST OF FIGURES

Figure 1: Global Nucleic Acid Therapeutics CDMO Market, Realistic and Optimistic Scenario, \$Million

Figure 2: Global Nucleic Acid Therapeutics CDMO Market, Market Dynamics

Figure 3: Share of Key Market Strategies and Developments, July 2017-July 2021

Figure 4: Growth Share Matrix for Global Nucleic Acid Therapeutics CDMO Market (by Company), 2019-2020

Figure 5: Global Nucleic Acid Therapeutics CDMO Market Research Methodology

Figure 6: Primary Research Methodology

Figure 7: Global Nucleic Acid Therapeutics CDMO Market, \$Million, 2020-2030

Figure 8: Optimistic View of Global Nucleic Acid Therapeutics CDMO Market, \$Million

Figure 9: Overview of CRO and CDMO Services

Figure 10: Global Nucleic Acid Therapeutics CDMO Market, Market Dynamics

Figure 11: Deal Value of Mergers and Acquisitions Involving Cell and Gene Therapies (2016-2019)

Figure 12: Share of Key Market Strategies and Developments, July 2017-July 2021

Figure 13: Share of Mergers and Acquisitions (by Company), 2017-2021

Figure 14: Share of Synergistic Activities (by Company), 2017-2021

Figure 15: Market Share Analysis for Global Nucleic Acid Therapeutics CDMO Market, 2020

Figure 16: Growth Share Matrix for Global Nucleic Acid Therapeutics CDMO Market (by Company), 2019- 2020

Figure 17: Global Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Method)

Figure 18: Share of Global Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Method), 2020 and 2030

Figure 19: Solid-Phase Oligonucleotide Synthesis Market Size and Forecast

Figure 20: Liquid-Phase Oligonucleotide Synthesis Market Size and Forecast

Figure 21: Share of Global Nucleic Acid Therapeutics CDMO Market (by Technology), 2020 and 2030

Figure 22: Global Nucleic Acid Therapeutics CDMO Market (by Column-Based Method), 2020-2030

Figure 23: Global Nucleic Acid Therapeutics CDMO Market (by Microarray-Based Method), 2020-2030

Figure 24: Global Nucleic Acid Therapeutics CDMO Market, by End User, 2020 and 2030 (\$Million)

Figure 25: Global Nucleic Acid Therapeutics CDMO Market, by Pharmaceutical and Biotechnology Companies

Figure 26: Global Nucleic Acid Therapeutics CDMO Market, by Academic Research Institutes

Figure 27: Global Nucleic Acid Therapeutics CDMO Market, by Diagnostic Laboratories

Figure 28: Global Nucleic Acid Therapeutics CDMO Market (by Product)

Figure 29: Share of Global Nucleic Acid Therapeutics CDMO Market (by Product), 2020 and 2030 (\$Million)

Figure 30: Global Nucleic Acid Therapeutics CDMO Market, by Standard Nucleic Acid

Figure 31: Global Nucleic Acid Therapeutics CDMO Market, by Micro-Scale Nucleic Acid

Figure 32: Global Nucleic Acid Therapeutics CDMO Market, by Large-Scale Nucleic Acid Market

Figure 33: Global Nucleic Acid Therapeutics CDMO Market, by Custom Nucleic Acid

Figure 34: Global Nucleic Acid Therapeutics CDMO Market, by Modified Nucleic Acid

Figure 35: Global Nucleic Acid Therapeutics CDMO Market Primer Market, by Primers

Figure 36: Global Nucleic Acid Therapeutics CDMO Market, by Primer

Figure 37: Global Nucleic Acid Therapeutics CDMO Market, by Others NA

Figure 38: Global Nucleic Acid Therapeutics CDMO Market, Other Services

Figure 39: Global Nucleic Acid Therapeutics CDMO Market (by Region), Million Units, 2020-2030

Figure 40: Share of North America Nucleic Acid Therapeutics CDMO Market Revenue (by Country), 2020-2030, \$Million

Figure 41: North America: Market Dynamics

Figure 42: U.S. Nucleic Acid Therapeutics CDMO Market, 2020-2030, \$Million

Figure 43: Canada Nucleic Acid Therapeutics CDMO Market, 2020-2030, \$Million

Figure 44: Share of Europe Nucleic Acid Therapeutics CDMO Market (by Country), 2020-2030, \$Million

Figure 45: Europe: Market Dynamics

Figure 46: Germany Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, \$Million

Figure 47: U.K. Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, \$Million

Figure 48: France Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, \$Million

Figure 49: Italy Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, \$Million

Figure 50: Spain Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, \$Million

Figure 51: Rest-of-Europe Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, \$Million

Figure 52: APAC: Market Dynamics

Figure 53: Asia-Pacific Nucleic Acid Therapeutics CDMO Market Revenue (by Country), 2020-2030, \$Million

Figure 54: China Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, \$Million

Figure 55: India Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, \$Million

Figure 56: Japan Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, \$Million

Figure 57: Australia Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, \$Million

Figure 58: Rest-of-Asia-Pacific Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, \$Million

Figure 59: Rest-of-the-World Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, \$Million

Figure 60: Shares of Key Company Profiles

Figure 61: Agilent Technologies, Inc.: Product Portfolio

Figure 62: Agilent Technologies, Inc.: Overall Financials, 2018-2020

Figure 63: Agilent Technologies, Inc.: Revenue (by Segment), 2018-2020

Figure 64: Agilent Technologies, Inc.: Revenue (by Region), 2018-2020

Figure 65: Agilent Technologies, Inc.: R&D Expenditure, 2018-2020

Figure 66: Agilent Technologies, Inc.: SWOT Analysis

Figure 67: Ajinomoto Co. Inc.: Overall Product Portfolio

Figure 68: Ajinomoto Co., Inc.: Overall Financials, 2017-2019

Figure 69: Ajinomoto Co., Inc.: Revenue (by Segment), 2017-2019

Figure 70: Ajinomoto Co., Inc.: SWOT Analysis

Figure 71: Bachem Holding AG.: Overall Product Portfolio

Figure 72: Bachem Holding AG.: SWOT Analysis

Figure 73: Biospring GmbH: Overall Product Portfolio

Figure 74: Biospring GmbH: SWOT Analysis

Figure 75: Corden Pharma International: Overall Product Portfolio

Figure 76: Corden Pharma International: SWOT Analysis

Figure 77: Danaher Corporation: Product Portfolio

Figure 78: Danaher Corporation: Overall Financials, 2018-2020

Figure 79: Danaher Corporation: Revenue (by Segment), 2018-2020

Figure 80: Danaher Corporation: Revenue (by Region), 2018-2020

Figure 81: Danaher Corporation: R&D Expenditure, 2018-2020

Figure 82: Danaher Corporation: SWOT Analysis

Figure 83: Guangzhou Ruibo Biotechnology Co., Ltd.: Product Portfolio

- Figure 84: Guangzhou Ruibo Biotechnology Co., Ltd: SWOT Analysis
- Figure 85: KNC Laboratories Co., Ltd.: Overall Product Portfolio
- Figure 86: KNC Laboratories Co., Ltd.: Overall Financials, 2018-2020
- Figure 87: KNC Laboratories Co., Ltd.: SWOT Analysis
- Figure 88: LGC Limited: Overall Product Portfolio
- Figure 89: LGC Limited: Overall Financials, 2018-2020
- Figure 90: LGC Limited: Revenue (by Segment), 2018-2020
- Figure 91: LGC Limited: R&D Expenditure, 2018-2020
- Figure 92: LGC Limited: SWOT Analysis
- Figure 93: Merck KGaA: Product Portfolio
- Figure 94: Merck KGaA: Overall Financials, 2018-2020
- Figure 95: Merck KGaA: Revenue (by Segment), 2018-2020
- Figure 96: Merck KGaA: Revenue (by Region), 2018-2020
- Figure 97: Merck KGaA: R&D Expenditure, 2018-2020
- Figure 98: Merck KGaA: SWOT Analysis
- Figure 99: Nippon Shokubai Co., Ltd.: Overall Financials, 2018-2020
- Figure 100: Nippon Shokubai Co., Ltd: Revenue (by Segment), 2018-2020
- Figure 101: Nippon Shokubai Co., Ltd: R&D Expenditure, 2018-2020
- Figure 102: Nippon Shokubai Co., Ltd: SWOT Analysis
- Figure 103: Nitto Denko Avecia Inc.: Product Portfolio
- Figure 104: Nitto Denko Avecia Inc.: SWOT Analysis
- Figure 105: QIAGEN N.V.: Product Portfolio
- Figure 106: QIAGEN N.V.: Overall Financials, 2018-2020
- Figure 107: QIAGEN N.V.: Revenue (by Segment), 2018-2020
- Figure 108: QIAGEN N.V.: Revenue (by Region), 2018-2020
- Figure 109: QIAGEN N.V.: R&D Expenditure, 2018-2020
- Figure 110: QIAGEN N.V.: SWOT Analysis
- Figure 111: ST Pharm Co Ltd : Overall Product Portfolio
- Figure 112: ST Pharm Co Ltd: SWOT Analysis
- Figure 113: Sumitomo Chemical Co., Ltd.: Overall Product Portfolio
- Figure 114: Sumitomo Chemical Co., Ltd: Overall Financials, 2018-2020
- Figure 115: Sumitomo Chemical Co., Ltd.: Revenue (by Segment), 2018-2020
- Figure 116: Sumitomo Chemical Co., Ltd: R&D Expenditure, 2018-2020
- Figure 117: Sumitomo Chemical Co., Ltd.: SWOT Analysis
- Figure 118: Syngene International Limited: Overall Product Portfolio
- Figure 119: Syngene International Limited: Overall Financials, 2018-2020
- Figure 120: Syngene International Limited: Revenue (by Region), 2018-2020
- Figure 121: Syngene International Limited: R&D Expenditure, 2018-2020
- Figure 122: Syngene International Limited: SWOT Analysis



- Figure 123: Thermo Fisher Scientific Inc.: Product Portfolio
- Figure 124: Thermo Fisher Scientific, Inc.: Overall Financials, 2018-2020
- Figure 125: Thermo Fisher Scientific Inc.: Revenue (by Segment): 2018-2020
- Figure 126: Thermo Fisher Scientific Inc.: Revenue (by Region), 2018-2020
- Figure 127: Thermo Fisher Scientific Inc.: R&D Expenditure, 2018-2020
- Figure 128: Thermo Fisher Scientific Inc.: SWOT Analysis
- Figure 129: Wuxi AppTec: Overall Product Portfolio
- Figure 130: Wuxi AppTec: Overall Financials, 2018-2020
- Figure 131: Wuxi AppTec: Revenue (by Segment), 2018-2020
- Figure 132: Wuxi AppTec: Revenue (by Region), 2018-2020
- Figure 133: Wuxi AppTec: R&D Expenditure, 2018-2020
- Figure 134: Wuxi AppTec: SWOT Analysis
- Figure 135: Yamasa Corporation: Overall Product Portfolio
- Figure 136: Yamasa Corporation: SWOT Analysis

## List Of Tables

### LIST OF TABLES

Table 1: Oligonucleotide Therapies Approved by the FDA

Table 2: Nucleic Acid Therapies Approved by FDA and EMA

Table 3: Companies offering Standard Nucleic Acid

Table 4: Companies offering Micro-Scale Nucleic Acid

Table 5: Companies offering Large-Scale Nucleic Acid

Table 6: Companies offering Custom Nucleic Acid

Table 7: Companies offering Modified Nucleic Acid

Table 8: Companies offering Primers

Table 9: Companies offering Probes

Table 10: Companies offering Other NA

Table 11: Companies offering Other Services



## I would like to order

Product name: Nucleic Acid Therapeutics CDMO Market - A Global and Regional Analysis: Focus on Product, Technology, and End User - Analysis and Forecast, 2021-2030

Product link: <https://marketpublishers.com/r/N37950CBE7A3EN.html>

Price: US\$ 7,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N37950CBE7A3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

